Pharmaceuticals

Liquidia Tech

Liquidia Corp Director Stephen M. Bloch Sells ~$14.28M in Shares

Liquidia Corp Director Stephen M. Bloch Sells $5.46M Worth of Shares

Liquidia Director Stephen M. Bloch Sells 319,000 shares of Common Stock

Liquidia Tech released FY2026 Q1 earnings on May 11 Pre-Market (EST), actual revenue USD 132.87 M (forecast USD 119.4 M), actual EPS USD 0.5199 (forecast USD 0.41)

Liquidia Tech to Release FY2026 Q1 Earnings on May 11 Pre-Market EST, Forecast Revenue USD 116.59 M, EPS USD 0.3688

Liquidia Tech released FY2025 Q4 earnings on March 5 Pre-Market (EST), actual revenue USD 92.02 M (forecast USD 87.49 M), actual EPS USD 0.1454 (forecast USD 0.2137)

Liquidia Tech released FY2025 earnings on March 5 Pre-Market (EST), actual revenue USD 158.32 M (forecast USD 153.82 M), actual EPS USD -0.8008 (forecast USD -0.7487)

Liquidia Tech to Release FY2025 Earnings on March 5, Pre-Market EST; Forecast Revenue USD 150.03 M, EPS USD -0.7862

Liquidia Corporation to Present New Clinical Data at PVRI 2026 Annual Meeting

Wall Street Zen Upgrades Liquidia Corporation Stock Rating to Buy

Liquidia Corporation announces preliminary net sales data for YUTREPIA in 2025 and business release progress

Guoyi Pharmaceutical Completes L606 Shipment and Launches Global Phase III Clinical Trials

Liquidia Corporation Shares Reach 52-Week High and Report Strong Revenue Growth

Liquidia Corporation's Chief Medical Officer Reports Sale of Common Stock

Y Intercept Hong Kong Ltd 增持 Liquidia Corporation 股票

Needham Raises Target Price for Liquidia to $52

Liquidia Tech released FY2025 9 Months Earnings on November 3 Pre-Market EST, with actual revenue of USD 66.3 M and EPS of USD -0.9771

Liquidia Tech released FY2025 Q3 earnings on November 3 Pre-Market (EST), actual revenue USD 54.34 M (forecast USD 18.86 M), actual EPS USD -0.0409 (forecast USD -0.4237)

Liquidia Reports Exceeding Revenue and Operational Profit in Q3

Liquidia Technologies and Vectura Limited Sign Exclusive License Agreement for Treprostinil in the U.S.

Freecast

Cuprina

U-BX Tech

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Defiance Pure Space Dly 2X Strat ETF

VS MEDIA

Everbright Digital

Park Ha Biological Tech

Friedman Industries

Defiance Daily Target 2X Short ASTS ETF

LQDA

Stephen M Bloch, a board member at Liquidia (NASDAQ:LQDA), sold 220,835 shares worth $14.27 million on June 10, as disclosed in an SEC Form 4 filing. Following the transaction, Liquidia's stock rose 6.89% to $69.75. The company reported significant revenue growth but faces challenges with high debt and overvaluation metrics compared to industry peers.

benzinga_article

Insider Selling: Stephen M Bloch Unloads $14.27M Of Liquidia Stock

Liquidia (LQDA) is scheduled to showcase four posters, which will feature ASCENT patient-reported cough outcomes, at the PHA 2026 International PH Conference in Dallas. The conference will host a diverse range of attendees and experts in the field.

Unusual Whales

Liquidia Announces Poster Presentations at the PHA 2026 International PH Conference and Scientific Sessions

Liquidia Technologies (LQDA) director Stephen Bloch sold 220,835 shares for $14.3M on June 10, 2026. Despite this insider sale, LQDA shares surged 18% to the mid-$60s, driven by its pending inclusion in the S&P SmallCap 600, a favorable Supreme Court ruling reducing legal risk for YUTREPIA, and improved profitability. TipRanks' AI analyst rates LQDA as an 'Outperform', citing strong technical momentum and commercial traction, though high valuation remains a constraint.

Tip Ranks

Hikma Pharmaceuticals Plc

Amarin

Major Insider Move at Liquidia Technologies Shakes Up Investor Watchlists

Liquidia Corp (LQDA) will be added to the S&P SmallCap 600 index effective before market open on June 22, 2026. The inclusion, based on criteria such as market cap and profitability, reflects the company's operational progress and aims to enhance its visibility among investors. Liquidia focuses on therapies for respiratory and vascular diseases using its PRINT technology.

TradingView

Liquidia added to S&P SmallCap 600 ahead of June 22 trading

SANM

SMTC

POOL

FLEX

S&P Dow Jones Indices announced quarterly rebalance changes effective June 22, 2026. Marvell Technology (MRVL) and Flex (FLEX) will be added to the S&P 500, replacing Pool Corp (POOL) and The Campbell's Company (CPB). Roku (ROKU), Coeur Mining (CDE), Semtech (SMTC), Sanmina (SANM), and Viavi Solutions (VIAV) join the S&P MidCap 400, while Flex is removed. Several companies including Pool, Campbell's, and Coty move between MidCap and SmallCap indices.

StockTitan

Sanmina

Semtech

The Campbells

Coty

Pool

Viavi Solutions

Flex

Coeur Mining

Roku

Marvell Tech

GraniteShares 2x Long MRVL Daily ETF

S&P 500

Bellring Brands

Concentrix

BlackBaud

Embecta

Universal Health Realty Income

Credit Acceptance

Oxford Industries

Lazard

Gogo

Eastern Bankshares

WesBanco

Insteel Industries

Warby Parker

Ethan Allen Interiors

Nicolet Bankshares

Cytek Biosciences

Monro

Rush Street Interactive

Vital Farms

US Lime & Minerals

Cable One

InvenTrust Properties

Forward Air

Dow Jones Industrial Average

S&P Global

Wesbanco Pref Shares 7.375 WSBC Perp 10/01/30

Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 | CDE Stock News

LABU

ARKG

SBIO

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 318,893 shares at an average price of $50.23, totaling approximately $16 million. Post-sale, he holds 1,870,042 shares, a 14.57% decrease in his position. The sale was disclosed to the SEC. Liquidia's stock recently opened at $57.59, with a market cap of $5.12 billion. The company reported a significant revenue increase of 4187.1% year-over-year and beat earnings expectations. Analysts have raised price targets, with a consensus rating of "Moderate Buy."

Market Beat

VG Health

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Health Care Select Sector SPDR

Direxion S&P Biotech Bull 3X

iShares Global Healthcare

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

iShares US Pharma

iShares Biotechnology ETF

ALPS Medical Breakthrough

Raymond James Financial

Oppenheimer

Wells Fargo

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Liquidia (NASDAQ:LQDA) Director Stephen Bloch Sells 318,893 Shares

Liquidia Corporation (NASDAQ:LQDA) has seen an increase in FY2028 EPS estimates by HC Wainwright, now projected at $6.37, up from $5.93. The firm maintains a "Buy" rating with a price target of $67.00. Other analysts have also raised their price targets, with Wells Fargo increasing theirs to $62.00. Liquidia's stock has recently traded up 6.5%, with a market cap of $5.03 billion. The company reported $0.52 EPS for the last quarter, exceeding estimates, and revenue surged 4187.1% year-over-year. Insiders have sold significant shares recently, indicating potential shifts in ownership.

Jefferies Financial

Liquidia FY2028 EPS Estimate Increased by HC Wainwright

Liquidia Corp (LQDA) reported strong Q1 results with earnings of 52 cents per share and sales of $132.865 million, surpassing analyst expectations. Following this, analysts raised their price targets: Wells Fargo's Benjamin Burnett increased it from $51 to $62, while HC Wainwright's Andrew S. Fein raised it from $55 to $67. Liquidia shares rose 3.1% to $54.80 after the announcement.

These Analysts Boost Their Forecasts On Liquidia After Upbeat Q1 Results

Liquidia Tech(LQDA.US)